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Neutrophil Elastase Cleaves PML-RAR
and Is Important for the Development
of Acute Promyelocytic Leukemia in Mice
clearly been defined (Bonnet and Dick, 1997; Turhan et
al., 1995), nor have the factors within that cell that must
interact with PML-RAR to initiate disease (Westervelt
and Ley, 1999). Regardless, PML-RAR is not sufficient
to cause APL on its own, since a long latent period is
Andrew A. Lane and Timothy J. Ley*
Division of Oncology
Departments of Medicine and Genetics
Siteman Cancer Center
Washington University School of Medicine
required for the development of disease in all models,St. Louis, Missouri 63110
implying that progression mutations are also critical.
Although the precise mutations responsible for progres-
sion are unknown, several different, recurring cytoge-Summary
netic abnormalities often accompany disease progres-
sion (Le Beau et al., 2002, 2003; Zimonjic et al., 2000).The fusion protein PML-RAR, generated by the
In addition, disregulated expression of BCL2 (Kogan ett(15;17)(q22;q11.2) translocation associated with acute
al., 2001), and activating mutations of FLT3 (Kelly et al.,promyelocytic leukemia (APL), initiates APL when ex-
2002; Sohal et al., 2003), can also synergize with PML-pressed in the early myeloid compartment of trans-
RAR to increase the likelihood that APL will developgenic mice. PML-RAR is cleaved in several positions
in a mouse.by a neutral serine protease in a human myeloid cell
We have recently described a distinct model of PML-line; purification revealed that the protease is neutro-
RAR-induced APL by knocking the PML-RAR cDNAphil elastase (NE). Immunofluorescence localization
into the murine cathepsin G locus (Westervelt et al.,studies suggested that the cleavage of PML-RAR
2003). This mutation creates a long latency model ofmust occur within the cell, and perhaps, within the
APL that has 100% penetrance, and a phenotype that isnucleus. The functional importance of NE for APL de-
essentially identical to the transgenic models describedvelopment was assessed in NE deficient mice. Greater
above. Although this model was created to increasethan 90% of bone marrow PML-RAR cleaving activity
PML-RAR expression by capturing regulatory informa-was lost in the absence of NE, and NE (but not Cathep-
tion from the cathepsin G domain, the expression levelsin G) deficient animals were protected from APL de-
of PML-RAR is only 2%–3% that of the transgenicvelopment. Primary mouse and human APL cells also
model. This data, coupled with additional observationscontain NE-dependent PML-RAR cleaving activity.
from our lab and others, suggested that PML-RARmaySince NE is maximally produced in promyelocytes, this
be toxic to early myeloid precursors (A.A.L. and T.J.L.,protease may play a role in APL pathogenesis by facili-
unpublished data) (Ferrucci et al., 1997; Grignani et al.,tating the leukemogenic potential of PML-RAR.
1993). Low levels of expression reduce this toxicity, per-
haps preserving the transformable “pool” of myeloidIntroduction
precursors, and/or permitting the gain-of-function prop-
erties of the PML-RAR to be more apparent. To exploreThe t(15;17) translocation that is present in more than
this possibility more fully, we transiently expressed90% of patients with acute promyelocytic leukemia
PML-RAR in myeloid versus nonmyeloid cell lines and(APL) creates two fusion proteins, PML-RAR and
were surprised to find that PML-RAR is rapidly andRAR-PML, and also creates haploinsufficiency for PML
predictably cleaved in the early myeloid cell line U937.and RAR (Melnick and Licht, 1999; Pollock et al., 2001).
The pattern of cleavage was similar when in vitro trans-All of these mutations could potentially be involved with
lated PML-RAR was incubated with murine bone mar-
the pathogenesis of this disease. However, PML-RAR
row extracts, suggesting that the same enzyme was
expression is required for the development of an APL-
responsible in humans and mice.
like disease in mice, and it defines the phenotype of the In this study, we have discovered that this proteolytic
myeloid leukemia that develops in animals. The timing activity is derived from neutrophil elastase (NE). The Ela2
of PML-RAR expression during myeloid development gene, which encodes NE, is transcriptionally activated in
appears to be important as well. Expression in late my- early myeloid development and expressed maximally at
eloid cells (directed by CD11b regulatory elements) the early promyelocyte stage (Fouret et al., 1989; Zimmer
caused minor changes in myeloid development and et al., 1992). Although the precise functions of the azuro-
does not cause APL (Early et al., 1996). However, trans- phil granule proteases (NE, cathepsin G, and proteinase
genic expression in early myeloid precursors (blasts and 3) have not yet been completely defined, they are
promyelocytes) using regulatory elements from MRP8 thought to be involved in host defense mechanisms
or cathepsin G results in myeloproliferation in all ani- provided by neutrophils (Belaaouaj et al., 2000; Tkal-
mals, and the development of APL-like disease in a small cevic et al., 2000). Heterozygous point mutations in the
fraction (Brown et al., 1997; Grisolano et al., 1997; He et human Ela2 gene are strongly associated with Cyclic
al., 1997). These results have suggested that the cellular Neutropenia and Severe Congenital Neutropenia (which
milieu in which PML-RAR is expressed is relevant for has an increased likelihood of AML development) (Hor-
its ability to initiate acute leukemia. However, the pheno- witz et al., 2003); the mechanism by which these muta-
type of the leukemia-initiating cell in APL has not yet tions alter myelopoiesis is unknown, as is their relevance
for the observations described here. However, simple
deficiency of NE in the mouse does not result in altered*Correspondence: tley@im.wustl.edu
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Figure 1. Analysis of PML-RAR Cleavage in Myeloid (U937) and Nonmyeloid (K562) Cells
(A) K562 and U937 were electroporated with a PML-RAR containing expression vector and harvested at the indicated times. Western blotting
was performed using RAR and actin-specific antibodies. Endogenous RAR levels are below the limit of detection of this blot.
(B) In vitro translated, 35S-methionine-labeled PML-RAR was incubated with the indicated amounts of K562 or U937 cell extracts. SDS-PAGE
separated samples were evaluated by autoradiography.
myeloid development, nor does it facilitate the develop- ence of a potent antiproteinase cocktail and immediately
harvested in RIPA buffer (see Experimental Procedures),ment of myeloid leukemia (Adkison et al., 2002; Be-
laaouaj et al., 1998; MacIvor et al., 1999; Pham and Ley, and since the cleavage pattern progresses as a function
of time after transfection (and not as function of time in1999). In this report, we show that both human and
mouse NE cleave PML-RAR, and that this enzyme is extraction buffer).
To measure PML-RAR cleavage in vitro, we gener-important for the development of APL in a high pene-
trance mouse model of this disease. ated 35S-methonine-labeled PML-RAR (using in vitro
transcription/translation) as a substrate for whole-cell
extracts derived from K562 or U937 cells. Unmanipu-Results
lated U937 cells (but not K562 cells) contained a pre-
formed protease activity that generated PML-RARPML-RAR Is Cleaved by a Preformed Protease
cleavage products of about 60 and 50 kDa, similar toin an Early Myeloid Cell Line
that of transfected U937 cells (Figure 1B; the preciseTo study the properties of cells transiently expressing
size of PML-RAR cleavage products may vary becausePML-RAR protein, we transfected several cell lines
of differences in protein folding and/or posttranslationalwith an expression vector (pcDNA3.1) containing a bcr-
modifications that differ between the native protein de-1-derived PML-RAR cDNA from a human APL patient
rived from U937 cells and the in vitro translated protein).(Grisolano et al., 1997). In K562 erythroleukemia cells,
Optimal reaction conditions for the U937 protease activ-we detected full-length PML-RAR protein as a 120 kDa
ity were also carefully defined: incubation at 37C for 15doublet that peaked in abundance 24 hr after transfec-
min in 300 mM NaCl and 25 mM Tris [pH 7.5] gavetion. In contrast, in U937 (early myelomonocytic) cells,
maximal cleavage (data not shown). K562 cell extractsPML-RAR protein was cleaved in a defined pattern
did not cleave PML-RAR under any conditions tested.over 24 hr, first generating products of 90 kDa and 60
kDa, and ultimately resulting in two dominant products
of approximately 50 and 52 kDa (Figure 1A). The appear- The PML-RAR-Cleaving Enzyme Is a Neutral
Serine Protease of Approximately 30 kDaance of these smaller bands is unlikely to be caused by
proteolysis that occurs during or after cell lysis, since The PML-RAR cleavage assay was performed in the
presence of multiple protease inhibitors, which revealedall of the samples were extracted identically in the pres-
Neutrophil Elastase and APL
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Figure 2. Purification of PML-RAR Cleaving Activity from U937 Cell Extracts
(A) Autoradiography of in vitro-translated 35S-labeled PML-RAR incubated with 25 g of U937 extract and the following protease inhibitors:
boiling for 5 min, 5 g/mL aprotinin, 5 g/mL chymostatin, 5 g/mL leupeptin, 5 g/mL pepstatin, 1 mM PMSF, 5 mM EDTA, 10 M ZVAD-
fmk, or 10 M D-fmk.
(B) Autoradiography of 35S-labeled PML-RAR treated with U937 extract fractions eluted from a gel filtration chromatography column is
shown. The elution fractions of molecular weight standards run on the same column are shown below: albumin, 70 kDa; ovalbumin, 49 kDa;
chymotrypsinogen A, 21 kDa; and ribonuclease A, 14 kDa.
(C) The final purification step of PML-RAR cleaving activity from U937 extracts over a heparin Sepharose column is shown. The starting
material represents pooled, dialyzed fractions containing maximal PML-RAR cleaving activity that eluted from a Q Sepharose anion exchange
column loaded with crude U937 extract. Peak activity elutes at 0.5 M NaCl.
(D) Coomassie staining of SDS-PAGE resolved proteins containing total U937 protein, fraction 13 from the final heparin Sepharose column,
and purified human NE, CG, and PR3, as indicated. Asterisks indicate the four proteins analyzed by mass spectrometry.
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that only boiling and the serine protease inhibitor PMSF type extracts (Figure 3B). However, while 3.3 and 1.1
g of extract (Figure 3B, lanes 5 and 6) from wild-typedemonstrated any inhibition of PML-RAR cleaving ac-
tivity (Figure 2A). Biochemical purification of the U937 or CG/ bone marrow extracts demonstrated complete
cleavage of full-length PML-RAR to two dominantprotease activity was carried out with column chroma-
tography using FPLC; column fractions were tested us- products of 50 and 60 kDa, most full-length PML-RAR
protein remained intact with NE/, NE/  CG/, oring the optimized cleavage conditions with radiolabeled
PML-RAR protein as the substrate. Superose 12 size DPPI/ bone marrow extracts (all of which lack NE)
tested at the same doses. Cleavage of full-length PML-fractionation revealed that PML-RAR cleaving activity
migrated between the ovalbumin and chymotrypsino- RARby NE/bone marrow extracts is therefore90%
less efficient than wild-type extracts (10 g of NE/gen A molecular weight standard peaks of 49 kDa and
21 kDa, respectively (Figure 2B). Biochemical purifica- extract is required to cleave all full-length PML-RAR,
compared to 1.1 g of wild-type extract).tion of the activity was performed via empiric testing of
binding and elution with numerous column matrices.
Optimal enrichment was obtained with sequential anion Human Neutrophil Elastase First Cleaves
exchange and heparin Sepharose columns (Figure 2C). Recombinant PML-RAR after V420 and V432
Coomassie staining of the most active fractions showed To define the sites of PML-RAR cleavage by NE, we
consistent association of a 30 kDa protein doublet with generated and purified recombinant His-tagged PML-
maximal PML-RAR cleaving activity (Figure 2D and RAR from E.coli via Co2 column purification. We puri-
data not shown). Mass spectrometric analysis of tryptic fied the initial NE-mediated cleavage products of recom-
digestion products from the four most abundant protein binant PML-RAR, which appeared as two bands of
bands in the most active fraction was performed (desig- approximately 58 and 60 kDa (data not shown). N-ter-
nated in Figure 2D). Peptides derived from the upper minal sequencing revealed that each band actually con-
two bands matched the proteins moesin and keratin, tained two peptide fragments generated by near simul-
which are not known to have protease activity. The lower taneous cleavage at two sites within the PML portion
30 kDa doublet contained a peptide signature that was of PML-RAR, (PMAV/V421) and (PVPV/Y433); these lo-
similar to that of the highly related azurophil granule cations are consistent with the known protease specific-
proteases cathepsin G (CG), neutrophil elastase (NE), ity of NE (Figure 4A) (Bode et al., 1989). These cleavage
and proteinase 3 (PR3); precise identity could not be events would be predicted to produce N-terminal and
assigned with certainty because of the high degree of C-terminal fragments of predicted sizes 52 kDa and 61
homology among these proteases. kDa, respectively (each are  1–2 kDa, which may ac-
count for the 12 amino acid intervening segment). To verify
the specificity of this cleavage event, valine to arginineThe Dominant-Cleavage Pattern by U937 Extracts
Is Most Similar to That of Neutrophil Elastase mutations were made to the P1 positions of both sites
(V420R and V432R), and a double-mutant PML-RARThe biochemical and mass spectrometric characteris-
tics of the purified activity suggested that PML-RAR protein was generated by in vitro transcription/transla-
tion. Reaction of the mutant PML-RARwith either U937cleavage was mediated by NE, CG, or PR3, which are
all known to be present in U937 cells (Welgus et al., extract or purified human NE verified the inability of the
protease to generate the dominant 60 kDa doublet1986). To determine which enzyme was responsible, we
obtained highly purified native human CG, NE, and PR3 (Figure 4B; only the C-terminal fragment is detected by
the RAR antibody used to detect PML-RAR). Minorand compared the cleavage patterns of in vitro tran-
scribed/translated PML-RAR with the purified activity cleavage products are not altered by the mutations.
These data suggest that initial cleavage of PML-RARfrom U937 cell extracts. While all three proteases
cleaved PML-RAR, purified human NE generated a is mediated by NE at these preferred sites, but that
cleavage by NE (and/or other enzymes) does occur atcleavage pattern that was the most similar to that
achieved with the U937-derived activity (Figure 3A). alternative positions.
Evidence for Intracellular PML-RAR CleavagePML-RAR Cleavage by Mouse Bone Marrow
Extracts Is Predominantly Mediated The subcellular localization of full-length PML-RAR
and its cleaved fragments was studied by two-colorby Neutrophil Elastase
To determine whether murine myeloid cells contain an immunofluorescence microscopy of transiently trans-
fected populations of K562 and U937 cells. Transfectedactivity that would cleave human PML-RAR, we incu-
bated in vitro translated human PML-RAR with total cells could easily be identified because of the intense
signals created by the overexpressed proteins producedbone marrow extracts made from wild-type, NE/,
CG/, NE/  CG/, or dipeptidyl peptidase I (DPPI) by the expression vector (pcDNA3.1); this reduced the
interpretation problems caused by the simultaneous de-deficient mice (all in the 129/Sv background). DPPI is
necessary for the activation of NE, CG, and PR3 (and tection of endogenous PML and RAR in these cells.
The N-terminal fragment of PML was detected with aother hematopoietic serine proteases); DPPI/mice are
functionally deficient for all three enzymes (Adkison et FITC-labeled (green) antibody, while the C-terminal re-
gion of RAR was detected with an AlexaFluor 594-al., 2002; McGuire et al., 1993). Mouse bone marrow
extracts contained an activity that cleaved PML-RAR labeled (red) antibody (the locations of the epitopes de-
tected by the antibodies are shown in Figure 4A). All cellswith virtually the same pattern as purified human NE
(Figure 3B). Extracts derived from the bone marrow of were stained with both antibodies. When we transiently
transfected the N-terminal portion of PML (amino acidsCG/ mice cleaved PML-RAR as efficiently as wild-
Neutrophil Elastase and APL
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Figure 3. U937 Extract and Mouse Bone Marrow Extract Cleave PML-RAR Similarly to Purified Human Neutrophil Elastase
(A) Western blotting against RAR is shown for the cleavage products of in vitro translated PML-RAR incubated with the indicated amounts
of purified U937 extract, or purified human neutrophil elastase, cathepsin G, or proteinase 3.
(B) Western blotting against RAR is shown for in vitro translated PML-RAR incubated with the indicated dilutions of bone marrow extracts
from 129/SvJ wild-type, NE/, CG/, NE/CG/, and DPPI/ mice. Lane 1, no enzyme. Lane 2, PR incubated with 40 nM human NE. Lanes
3–9, 3-fold dilutions of bone marrow extracts from the indicated mouse genotypes, beginning with 30 g of total protein.
Cell
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Figure 4. Identification of NE Cleavage Sites in PML-RAR and Subcellular Localization of the Cleavage Products
(A) Arrows indicate the position of NE cleavage within the PML portion of PML-RAR, after V420 and V432. The approximate expected sizes
of the peptide fragments generated by these cleavage events are shown. Several known domains in PML-RAR are labeled: cystine-rich
RING/B Box domain (Cys Rich), helical coiled-coil domain (Coiled), nuclear localization signal (NLS), transcriptional activation domain (AF-2),
DNA binding domain (DBD), and the ligand binding domain (LBD). Asterisks indicate the epitopes recognized by the antibodies used in
immunofluorescence microscopy for detecting PML (green) and RAR (red).
(B) Western blotting against RAR is shown for in vitro-translated wild-type PML-RAR or a cleavage site double mutant (V420R/V432R).
Wild-type or mutant PML-RAR was incubated with 5 g of crude U937 extract or 10 nM purified human NE. Uncleaved in vitro translated
PML-RAR is shown in lane 1 as a reference.
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1–420, which contains PML sequences without a nuclear of observation (Figure 5A, p  0.0001) The decreased
penetrance of APL with NE deficiency is specific, since,localization signal [NLS]) into K562 or U937 cells, the
transfected PML protein was detected as large cyto- as reported in the original description of the CG/PR
model, mice deficient for the related serine protease,plasmic aggregates. This pattern is consistent with the
reported cytoplasmic aggregation of full-length PML cathepsin G, do not display reduced APL penetrance
(Figure 5B, p 	 0.56) (Westervelt et al., 2003).lacking its NLS (Le et al., 1996). When we transfected
the C-terminal fragment of PML-RAR (amino acids
433–933, containing the PML nuclear localization signal APL Arising in NE/ Versus NE/ Mice
Is Phenotypically Similarplus the RAR portion of PML-RAR), this protein was
detected in a homogeneous nuclear pattern, similar to Although the probability of developing APL was signifi-
cantly reduced in the NE/ animals, the phenotype ofthat of endogenous RAR. Cotransfection of both frag-
ments revealed an identical localization pattern as cells leukemias arising in the NE/ and NE/ mice was simi-
lar (Supplemental Figures S1A and S1B available atexpressing each respective fragment alone (Figure 4C);
confocal microscopy confirmed the lack of association http://www.cell.com/cgi/content/full/115/3/305/DC1).
Tumor cell morphology was indistinguishable. Bothof the two fragments (data not shown). These data sug-
gest that the downstream fragment of RAR (containing NE/ and NE/ leukemic cells display aberrant coex-
pression of CD34 and Gr-1 (Supplemental Figures S1Athe NLS) does not “chaperone” the PML portion of the
molecule into the nucleus when the two fragments are and S1C available on Cell website). A preleukemic phe-
notype of splenic myeloid expansion and an aberrantexpressed separately.
Whole-cell immunofluorescence of K562 and U937 CD34/Gr-1 double-positive population was observed in
all 8-week-old CG/PRNE/ and CG/PRNE/ animalscells transfected with full-length PML-RAR demon-
strated the expected “microspeckled” nuclear pattern (p 0.01, for all CG/PR versus all CG/ animals; Supple-
mental Figure S1C available on Cell website). Althoughwith both PML and RAR specific antibodies (Figure
4C). To determine whether the PML and RAR portions the penetrance of APL is only 15%–20% in hCG-PML-
RAR mice, all animals display the same preleukemicof the molecule colocalized within these subnuclear
structures, we used confocal microscopy to examine myeloproliferative syndrome as that found in the
mCG/PR model, which displays 100% penetrance for0.1–0.2 m sections of the transfected cells. In K562
cells 24 hr posttransfection (where virtually all PML- APL (Grisolano et al., 1997; Westervelt et al., 2003).
We previously showed that full-length PML-RARRAR protein is full-length by Western, see Figure 1A),
confocal microscopy demonstrated almost complete protein cannot be detected from either transgenic or
knockin derived APL cells; however, in transgenic APLoverlap of the microspeckled fluorescence signals from
PML and RAR (Figure 4D). In contrast, in U937 cells cells (which express50 times more PML-RARmRNA
than the knockin cells), the only transgene-specific pro-examined 24 hr after transfection (where about half of
the PML-RAR is cleaved, Figure 1A), the microspeckled tein detected by anti-RAR Western blotting was a 50
kDa band, suggesting the possibility that the PML-RARPML and RAR signals did not overlap completely in
any cell examined (Figure 4D). This suggests that some protein was cleaved in the APL cells (Westervelt et al.,
2003). As expected, neither NE/ nor NE/ APL cellsof the PML-RAR in these cells was cleaved intracellu-
larly, allowing the cleavage products to localize within contained detectable quantities of full-length PML-
RAR (data not shown).discrete areas within the nucleus. Similar studies cannot
be accurately interpreted in primary APL cells, since To determine whether the penetrance phenotype was
influenced by an unexpected effect of NE deficiency onendogenous PML and RAR proteins would also be
present in similar amounts. PML-RAR expression, we used quantitative RT-PCR
to measure levels of PML-RAR mRNA in NE/ versus
NE/ APL cells. As shown in Figure 5C, tumors derived
from either background contained similar amounts ofMice Deficient for NE Are Less Likely to Develop APL
To determine whether NE is relevant for the develop- PML-RARmRNA. NE/ tumors did not contain detect-
able amounts of NE mRNA, as expected.ment of APL in mice, we intercrossed knockin mice
expressing PML-RAR driven by the mouse CG locus To determine whether primary murine APL cells con-
tained the PML-RAR cleaving activity, we made cell ex-(CG/PR) with NE knockout mice that have previously
been characterized (Belaaouaj et al., 1998). CG/PRNE/ tracts from leukemic spleens derived from CG/PRNE/,
CG/PRNE/, and CG-/PRNE/ mice with similar tumormice developed APL with the expected 150–200 day
latency and demonstrated 100% penetrance of APL at cell compositions (41.9%, 52.7%, and 43.3% CD34/
Gr-1 cells, respectively). PML-RAR cleaving activity350 days (Westervelt et al., 2003). CG/PRNE/ animals
developed APL with only 45% penetrance after 350 days was present in extracts derived from wild-type and
(C) Immunofluorescence microscopy for K562 and U937 cells 24 hr after electroporation with the indicated expression constructs is shown.
Cells were electroporated with vector alone, the N-terminal cleavage product of PML-RAR (aa 1–420), the C-terminal product (aa 433–933),
both (aa 1–420  433–933), or full-length PML-RAR (aa 1–933). All cells in (C) and (D) were stained with both anti-PML and anti-RAR
antibodies. Green 	 anti-PML fluorescence, Red 	 RAR, Blue 	 nuclei visualized by DAPI stain.
(D) Merged confocal images (24 hr postelectroporation) of representative thin sections through two separate K562 and two separate U937
nuclei, each transfected with full-length PML-RAR, are shown. Green, anti-PML fluorescence; Red, RAR; Yellow, colocalization of the PML
and RAR fluorescence signals.
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Figure 5. Development of Acute Myeloid Leukemia in CG/PRNE/ Versus CG/PRNE/ Animals
(A) The Kaplan-Meier probability of leukemia-free survival of wild-type CG/NE/ (filled circles, n 	 18 mice), CG/NE/ (open circles, n 	
10), CG/PRNE/ (open squares, n 	 33), and CG/PRNE/ (filled squares, n 	 31) animals is plotted against time from birth. The difference
between the CG/PRNE/ and the CG/PRNE/ curves is statistically significant (p  0.0001).
(B) The Kaplan-Meier probability of leukemia-free survival of animals carrying a single PML-RAR knockin gene (which also creates a null
cathepsin G allele) together with either an intact CG gene (CG/PR, filled squares, n 	 37), or a null mutation of the residual CG allele (CG-/PR,
open triangles, n 	 28) is plotted against time from birth. CG-/PR mice are completely null for cathepsin G. The difference between the curves
is not statistically significant (p 	 0.56). The data shown in (B) appeared in Westervelt et al. (2003; copyright American Society of Hematology,
used with permission), and is shown only for ease of comparison.
(C) Real-time RT-PCR analysis of the relative abundance of PML-RAR and NE mRNAs in wild-type C57Bl/6  129/SvJ F1 splenocytes, CG/
PRNE/ tumors, and CG/PRNE/ tumors. Data represent normalized mean mRNA levels relative to GAPDH mRNA levels plus or minus one
standard deviation for three wild-type animals, and three independent tumors representing each genotype, each assayed in triplicate.
(D) Western blotting against RAR for in vitro-translated PML-RAR incubated with the indicated dilutions of extracts from CG/PRNE/, CG/
PRNE/, and CG-/PRNE/ APL cells. Lane 1, no enzyme. Lane 2, PR incubated with 40 nM human NE. Lanes 3–9, 3-fold dilutions of APL cell
extracts from the indicated mouse genotypes beginning with 30 g total protein.
cathepsin G deficient APL cells (Figure 5D), but was RAR fusion mRNA, which predicts a fusion protein of
90 kDa. Western blotting performed on lysates madereduced more than 10-fold in NE-deficient APL cell ex-
tracts (Figure 5D). from the primary AML cells (which were prepared in
RIPA buffer containing the protease inhibitor cocktail
used in Figure 1) showed that none of the M3 samplesAPL Cells Derived from Human Patients Contain
PML-RAR Cleaving Activity expressed full-length 120 kDa PML-RAR. Instead, each
contained multiple smaller protein fragments recog-Primary leukemia cells were obtained from the bone
marrow of four patients with de novo FAB M3 AML (APL) nized by the anti-RAR antibody (Figure 6A, lanes 3–5).
The extract from the sample with the bcr-3 fusion didand two patients with de novo M2 AML as negative
controls. We first characterized the fusion breakpoints not contain detectable amounts of PML-RAR (Figure
6A, lane 6), even though a fusion cDNA obtained fromof PML-RAR in the four M3 samples so that we could
predict the lengths of the expected fusion proteins. APL this sample expressed the expected 90 kDa protein
when translated in vitro (Figure 6D). Samples derivedcells from patients 11472, 14419, and 18719 contained
a bcr-1 PML-RAR fusion mRNA, which predicts a pro- from M2 AML cells contained no detectable PML-RAR
protein, as expected.tein of 120 kDa. Patient 22114 expressed a bcr-3 PML-
Neutrophil Elastase and APL
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To determine whether the same primary APL cells mine whether NE is important for APL pathogenesis, we
examined the development of APL in mice deficient forcontained PML-RAR cleaving activity, we made an in-
this enzyme. These mice developed APL that is pheno-dependent set of cell lysates from the same samples,
typically similar to that which occurs in NE/ animals,using conditions that favored the extraction of active
but the penetrance of APL development was signifi-proteases. Incubation of in vitro translated PML-RAR
cantly reduced. Together, these data suggest that NEwith extracts made from the four APL samples revealed
is important for the ability of PML-RAR to initiate APLcleavage in a pattern that was similar to that of purified
in transgenic mouse models of disease. Since PML-human NE. This cleavage was almost fully inhibited by
RAR is also cleaved by NE that is present in humanpreincubation of the crude APL cell extracts with
APL cells, it could also play a role in the pathogenesisGW311616A, a small molecule that specifically inhibits
of the human disease.the activity of NE (Figure 6B, lanes 13–16) (Macdonald
Several lines of evidence have suggested that PML-et al., 2001). The dominant PML-RAR cleaving activity
RAR requires an interaction with a factor(s) presentin human APL cells would therefore appear to be due
in early myeloid cells in order to initiate disease. Theto NE.
hallmark of APL is the accumulation of promyelocytes;The bcr-3 form of PML-RAR does not contain the
this morphologic sine qua non distinguishes it from allPML sequences containing the preferred cleavage sites
other kinds of AML and has long suggested that someidentified in Figure 4. To determine whether this isoform
key characteristic of promyelocytes was important forcould also be cleaved by NE, we cloned the bcr-3 PML-
the development of this disease. The leukemia-initiatingRAR cDNA from patient 22114 and generated in vitro
cell for APL likewise appears to be different from thetranslated PML-RAR protein for use in the in vitro
other AML subtypes, in that the initiating cell is notcleavage assay. NE-mediated cleavage of bcr-3 PML-
clearly present within the CD34/CD33 population de-RAR did occur, but it generated different sized frag-
fined by Dick and colleagues to contain the initiatingments from that of bcr-1 PML-RAR (Figure 6C). Al-
cells for other kinds of AML (Bonnet and Dick, 1997).though the NE cleavage sites in the PML domain of
When PML-RAR was targeted to the postmitotic my-bcr-1 PML-RAR are preferred, this protease can clearly
eloid compartment with CD11b regulatory elements, thecleave this molecule in other positions (also see Fig-
full-length protein was expressed, but no APL devel-ure 4B).
oped (Early et al., 1996). When expressed under the
control of either cathepsin G or MRP8 regulatory se-The Human APL Cell Line NB4, which Expresses
quences, which are activated at the blast/promyelocyteFull-Length PML-RAR, Does Not Contain NE Activity
stage of development, all animals develop myeloprolif-NB4, a well studied cell line developed from a t(15;17)
erative disease, and some go on to develop a lethalpositive APL patient, contain the bcr-1 isoform of PML-
APL-like disease (Brown et al., 1997; Grisolano et al.,RAR. In contrast to primary APL cells containing the
1997; He et al., 1997). Finally, when PML-RAR is ex-bcr-1 fusion, NB4 cells express the predicted 120 kDa
pressed in all hematopoietic progenitors using a retrovi-PML-RAR protein by Western blotting (Figure 6A, lane
ral vector, the animals only develop APL, not other he-9) (Fanelli et al., 1999; Jing et al., 2003; Zhu et al., 1999).
matopoietic malignancies (Minucci et al., 2002). All ofTo determine whether these cells contain PML-RAR
these results suggest that the specific “soil” of earlycleaving activity, we made extracts from this line before
myeloid cells is critical for the oncogenic PML-RARor after 3 days of ATRA-induced differentiation. Neither
“seed” to flourish and produce disease (Figure 7) (West-extract significantly cleaved PML-RAR in vitro (Figure
ervelt and Ley, 1999).
6B, lanes 11 and 12). To verify and quantitate this result,
Many lines of evidence presented in this report sug-
we compared the abilities of a variety of cell extracts
gest that PML-RAR is cleaved specifically in primary
to cleave CG or NE-specific peptide substrates. U937
mouse and human APL cells, and that NE is the dominant
extracts and all four human APL cell extracts contained
activity responsible for this cleavage event. We were not
substantial amounts of NE and CG activity (Figure 6D), able to detect full-length PML-RAR protein in primary
with quantities similar to that previously estimated for human APL cells; only truncated proteins were detected
human neutrophils (Campbell et al., 1989). In contrast, by the RAR specific antibody. In contrast, NB4 cells
K562 and NB4 extracts (before or after ATRA treatment) contained the full-length 120 kDa, bcr-1 derived PML-
did not contain measurable quantities of these activities RAR protein. While human APL cells were found to
(Figure 6D). contain abundant NE and CG activities, NB4 cells did
not contain PML-RAR cleaving activity or measurable
Discussion amounts of NE or CG. These data suggest that NB4
cells may be frozen at a developmental stage that is
In this report, we show that the PML-RAR fusion protein different from that of primary APL cells, or that these
can be cleaved by neutrophil elastase, a neutral serine cells may have lost NE and CG expression as an adapta-
protease that is maximally produced in promyelocytes. tion for survival in vitro.
The initial NE cleavage events occur in the C-terminal The PML-RAR cleaving activity in primary APL cells
domain of the PML portion of the fusion protein, but was nearly eliminated with a highly specific small mole-
other cleavage sites are clearly present as well. Mouse cule inhibitor of NE, despite the fact that these cells
bone-marrow extracts cleave human PML-RAR in a contain large amounts of CG activity (and large amounts
pattern that is similar to human NE; NE is the dominant of PR3 mRNA, data not shown). Similarly, by assaying
PML-RAR cleaving activity in these cells. Similarly, the murine bone marrow extracts and murine APL cells
dominant PML-RAR cleaving activity in both mouse made from NE versus CG deficient mice, we could as-
sign PML-RAR cleaving activity almost entirely to NE.and human APL cells appears to be that of NE. To deter-
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Figure 6. PML-RAR Cleaving Activity Is Due to NE in Primary Human M3 AML Cells
(A) Western blotting against RAR and actin in extracts made from primary bone marrow AML cells. Extracts were prepared by lysing cells
in RIPA buffer containing a cocktail of proteinase inhibitors, as described in Experimental Procedures. Lanes 1 and 2 represent K562 cells
electroporated with vector alone or vector containing bcr-1 PML-RAR as a reference. Leukemic bone marrow cells from patients 11472 (lane
3), 14419 (4), and 18719 (5) harbor a bcr-1 PML-RAR mRNA. Patient 22114 (lane 6) harbors a bcr-3 PML-RAR mRNA.
(B) Western blotting against RAR for in vitro-translated PML-RAR incubated alone (lane 1), with 40 nM purified human NE (lanes 2, 13, and
14), with 40 nM purified human CG (lanes 15 and 16), or with 2.5 g of crude cell extracts from the indicated human APL samples, or from
NB4 cells before or after differentiation with ATRA. Extracts were preincubated with or without 10 M GW311616A, a specific inhibitor of NE,
as indicated.
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Figure 7. Model for the Interaction of Neutro-
phil Elastase and PML-RAR in Mouse Mod-
els of APL
Neutrophil elastase protein production (green
curve) is maximal in the promyelocyte com-
partment of myeloid maturation. MRP8, CG,
and retroviral driven mouse models of APL
(red) all direct expression of PML-RAR to
the promyelocyte compartment, where NE is
produced; all result in APL. The retrovirally
driven model causes PML-RAR to be ex-
pressed outside of the promyelocytic com-
partment and in other hematopoietic lin-
eages, but the only leukemia that develops in
these mice is APL. CD11b (blue) drives PML-
RAR expression after NE expression occurs
and does not cause APL.
All of our studies of endogenous PML-RAR were per- transport mechanism that is not yet clear. Furthermore,
serpins directed against Granzyme B (PI-9) and NEformed using conditions that would strongly inhibit any
postlysis cleavage of this protein; furthermore, the addi- (MNEI/PI-2), can be found in the nuclei of some cells
that express these enzymes, where they may be presenttion of the specific NE inhibitor GW311616A to cells
before lysis did not further inhibit cleavage, suggesting to protect cells from small quantities of “leaking” en-
zymes (Bird et al., 2001).that all of the detected cleavage occurred intracellularly,
and not as a “postlytic” artifact. This idea was also The initial cleavage sites of PML-RAR in the C-ter-
minal domain of PML would not be expected to alterstrongly supported by confocal imaging studies of trans-
fected PML-RAR in U937 cells, where the N-terminal the dimerization motifs of either the PML or RAR por-
tions of the molecule. However, the initial cleavageand C-terminal portions of the protein were found to
be segregated in discrete subnuclear structures. This events are not the only ones that occur (see Figure 4B);
additional sites of NE-induced cleavage are unaffectedseparation clearly must occur intracellularly, since these
cells were fixed in situ and never lysed. by the mutations at positions 420 and 432. Furthermore,
we analyzed the NE-induced cleavage of a bcr-3 isoformThe normal trafficking of NE to the azurophil granules
(which are specialized lysosomes) raises the question of PML-RAR from an APL patient, which does not con-
tain this region of PML in the fusion protein. This mole-of how this enzyme could encounter PML-RAR, which
is transported to the nucleus after synthesis in the ER. cule is also cleaved, but in different positions from bcr-1.
These data suggest that it may not be the precise siteAlthough the answer is unknown, it is formally possible
that NE destined for the cell surface may contact PML- of cleavage that is critical, but it is important that PML-
RAR is cleaved. Clearly, the cleaving enzyme itself isRAR in the late ER or cytosol (Owen et al., 1995). Alter-
natively, since massive amounts of NE are produced in also relevant. NE, CG, and PR3 all cleave recombinant
PML-RAR (Figure 3A), but the dominant activity inearly promyelocytes (1%–2% of the wet weight of a
neutrophil is comprised of this enzyme, see Figure 6 crude extracts made from cells containing all three pro-
teases is clearly that of NE. In addition, NE deficiencyand Campbell et al., 1989), a small portion may escape
normal trafficking controls and encounter PML-RAR protects mice from APL, while CG deficiency does not,
even though both proteases can cleave PML-RAR.elsewhere in the cell. The combined data from the immu-
nofluorescence studies actually suggests that PML- We do not yet understand the mechanism by which
neutrophil elastase deficiency protects mice from PML-RAR may be cleaved inside the nucleus, since the
N-terminal part of PML, when transfected alone or in RAR initiated APL. Our data supports the hypothesis
that NE cleavage of PML-RAR creates a modified formcombination with the NLS-RAR, does not appear to
enter the nucleus. This idea is not implausible, since of this protein that is important for the initiation of APL.
The cleaved portions of PML-RAR appear to form ho-two closely related serine proteases, Granzyme A (Jans
et al., 1998) and Granzyme B (Jans et al., 1996; Trapani motypic aggregates in the nuclei of cells that may have
unique gain-of-function properties. The cleaved por-et al., 1996) can also enter the nucleus of cells. Like the
azurophil granule proteases of promyelocytes, gran- tions of the molecule could also interact with other pro-
teins, altering their functions. Clearly, further work willzymes are normally stored in the specialized granules of
cytotoxic lymphocytes, which are secretory lysosomes. be required to understand this potential mechanism.
Alternatively, NE deficiency could be potentially alterWhen granzymes enter target cells, they are rapidly
transported from the cytoplasm into the nucleus, via a myeloid development, decreasing the size of the trans-
(C) Western blotting against RAR is shown for the cleavage products of in vitro translated bcr-1 and bcr-3 PML-RAR incubated with the
indicated amounts of purified human neutrophil elastase.
(D) In vitro NE or CG activity of crude cell extracts derived from the indicated cell lines or primary human APL cells. NB4 extracts were made
either before or after 72 hr of incubation with 1M ATRA. The relative amount of peptide cleavage activity per g of total cell extract is
expressed relative to the activity of 1 ng of purified human NE or CG. Data represent means plus or minus standard deviations of each lysate,
assayed in triplicate.
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Transfection and Western Blottingformable pool of myeloid precursors that possess the
1 107 cells were electroporated with 50 g of supercoiled plasmidcorrect environment for PML-RAR-initiated disease.
DNA containing the bcr-1 PML-RAR cDNA in pcDNA3.1 (In-There is little evidence for this hypothesis, since NE
vitrogen). Cells were harvested at various time points after electro-
deficient mice have normal numbers of hematopoietic poration and cell lysates were prepared by incubation in RIPA buffer
progenitors, and since their myeloid development is not (150 mM NaCl, 50 mM Tris [pH 7.5], 1 mM EDTA, 0.1%SDS, 0.5%
sodium deoxycholate, 1% NP-40, 1 mM PMSF, and a protease inhibitormeasurably altered (Belaaouaj et al., 1998; Tkalcevic et
cocktail [Sigma] containing 10 mM AEBSF, 8 M aprotinin, 0.2 mMal., 2000). Furthermore, complete NE loss-of-function in
leupeptin, 0.4 mM bestatin, 0.2 mM pepstatin A, 0.1 mM E-64, withDPPI deficient human patients is not associated with
or without 10 M GW311616A). Western blotting was performed asaltered neutrophil counts, although extensive studies
previously described (Westervelt et al., 2003), using a polyclonal
of myelopoiesis have not yet been performed in these rabbit anti-RAR antibody (C-20, Santa Cruz) or a polyclonal antiac-
patients (C.T.N. Pham and T.J.L., unpublished data). tin antibody (C-11, Santa Cruz).
It is not likely that the effects described here are due
to technical aspects of the model systems. Although the In Vitro Cleavage Assays
To make crude cellular extracts containing active proteases, cellsNE deficient mice contain a retained PGK-neo cassette in
were incubated in RSB buffer (10 mM Tris [pH 7.4], 10 mM NaCl, 3the Ela2 gene, neighborhood effects on expression of
mM MgCl2, 0.1% NP-40) on ice for 10 min and nuclei were removedthe tightly linked PR3 gene have not been detected
by centrifugation. The supernatants were harvested and protein
(Belaaouaj et al., 1998). Furthermore, our intercross contents were determined. 35S-labeled PML-RAR was generated
strategy with the NE and CG deficient mice, which are via the T7 promoter using pcDNA3.1-PML-RAR and the TnT Quick
Coupled Transcription/Translation System (Promega) per the manu-both in a 129/Sv background, would make it extremely
facturers instructions. Optimized cleavage assays were performedunlikely that a strain difference could account for
in 300 mM NaCl, 50 mM Tris [pH 7.5], at 37C for 15 min, in thethese results.
presence or absence of the NE inhibitor GW311616A (GlaxoSmith-In sum, the data reported here strongly suggests that
Kline). The reaction was stopped by boiling in SDS loading buffer
NE is important for the ability of PML-RAR to initiate and proteins were resolved with SDS-PAGE for visualization by auto-
APL. NE is produced at maximal levels in promyelocytes, radiography, or were transferred to PVDF membranes for Western
blotting. Purified human NE, CG, and PR3 were obtained from Elastinthe cell type that accumulates in patients with this dis-
Products Company (Owensville, MO). Murine bone marrow extractsease. NE-mediated cleavage of PML-RAR may some-
were generated by flushing mouse femora and tibiae in HBSS, fol-how alter its activity, making it more likely that PML-
lowed by red cell lysis and disruption of the cell pellets by sonication.RAR will cause APL. These data raise many important
Cleavage assays using a synthetic peptide substrate for NE or CG
questions about the roles of proteases for leukemia were performed as previously described (MacIvor et al., 1999).
pathogenesis, especially in light of recent data that the
MLL protein is also cleaved and activated in hematopoi- Protease Purification
U937 extract in cleavage assay buffer was applied to a Superoseetic cells (Hsieh et al., 2003; Yokoyama et al., 2002).
12 gel filtration column for molecular mass determination. RelativeTogether, these observations suggest that hematopoi-
migration was determined using a protein standard calibration kitetic proteases may play important roles in the develop-
(Amersham). U937 extracts in RSB buffer were applied to a Q Sepha-ment of certain kinds of leukemia, and that inhibitors of
rose anion exchange column and eluted with a linear 0–1 M NaCl
these enzymes should be evaluated for their impact gradient. Active fractions eluted at 0.3 M NaCl. Fractions with
on disease. PML-RAR-cleaving activity were pooled, dialyzed against 10 mM
NaCl, 25 mM Tris [pH 7.5], applied to a heparin Sepharose column,
and eluted with a linear 0–1 M NaCl gradient. The most active frac-Experimental Procedures
tions eluted at an NaCl concentration of 0.5 M NaCl. All active
fractions were analyzed by SDS-PAGE followed by silver or Coo-Mice
massie staining to examine for enrichment of specific protein bands.mCGPR/PR, NE/, and CG/ animals have been previously described
MALDI-TOF and LC-mass spectrometric analysis of purified pro-(Belaaouaj et al., 1998; MacIvor et al., 1999; Westervelt et al., 2003).
teins was performed by the Washington University Protein and Nu-The breeding of cathepsin G-driven PML-RAR into an NE deficient
cleic Acid Chemistry Laboratory (PNACL).background was accomplished by mating 6 homozygous mCGPR/PR
mice (129/SvJC57Bl/6 F1 background) with 6 homozygous NE/
mice (on a 129/SvEv background), which generated an F1 generation Cleavage Site Analysis
with obligate double heterozygous (mCG/PRNE/) genotypes. Ten Recombinant His-tagged PML-RAR was produced in BL21(DE3)-
of these double heterozygote-breeding pairs yielded approximately RIL cells and purified over a TALON Co2 affinity column per the
200 F2 progeny containing all of the genotypes studied here. All manufacturer’s instructions (BD Biosciences). Purified PML-RAR
mice were genotyped with PCR or Southern based strategies, as was incubated with human NE, and the resulting products were
previously described. Mice obtained from all 10 breeding pairs gen- excised from Coomassie-stained PVDF membranes and subjected
erated similar phenotypes. Generation of CG-driven PML-RAR in to N-terminal sequencing by the Washington University PNACL.
the context of CG deficiency (129/SvJ background) was performed Cleavage site mutants were generated using the QuikChange Site-
similarly, as previously described (Westervelt et al., 2003). All geno- Directed Mutagenesis Kit per the manufacturer’s instructions (Stra-
types were identified directly by Southern blotting or PCR detection tagene).
of the indicated mutation.
Immunofluorescence/Confocal Microscopy
2 105 electroporated cells were affixed to glass slides by centrifu-Human AML Samples
Cryopreserved M2 and M3 AML cells were obtained from the Leuke- gation, air dried, and then fixed in 100% methanol at 20C. After
blocking with 2% goat serum in TBST, slides were incubated withmia Bank of the Siteman Cancer Center Tissue Procurement Core.
All patients gave informed consent for tissue banking, using a Wash- mouse monoclonal anti-PML (PG-M3, Santa Cruz) or rabbit poly-
clonal anti-RAR (C-20, Santa Cruz), diluted 1:200 in TBST/goatington University Medical School IRB approved protocol. Protein
and total RNA was harvested from the cells as previously described serum. Secondary antibodies diluted 1:200 in TBST/goat serum in-
cluded goat antimouse FITC (Vector) and goat antirabbit AlexaFluor(Westervelt et al., 2003). RT-PCR analysis of the t(15;17) breakpoint
in these cells was performed using the P3/R4a primer set, as pre- 594 (Molecular Probes). Cells were mounted in medium containing
DAPI and visualized by standard immunofluorescence microscopy.viously described (Gallagher et al., 1995).
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The brightest fluorescent cells in the field were examined, as repre- Ferrucci, P.R., Grignani, F., Pearson, M., Fagioli, M., Nicoletti, I., and
Pelicci, P.G. (1997). Cell death induction by the acute promyelocyticsentatives of the highest expressing cells in the transfected popula-
tion. Confocal microscopy was performed on the same slides using leukemia-specific PML/RAR fusion protein. Proc. Natl. Acad. Sci.
USA 94, 10901–10906.a Zeiss LSM-510 microscope. Images are overlays of red and green
fluorescence detected in one of twenty 100–200 nm slices through Fouret, P., DuBois, R.M., Bernaudin, J.-F., Takahashi, H., Ferrans,
each cell. V.J., and Crystal, R.G. (1989). Expression of the neutrophil elastase
gene during human bone marrow cell differentiation. J. Exp. Med.
Leukemia Development and Tumor Cell Analysis 169, 833–845.
Monitoring for leukemia in transgenic mice, cryopreservation of tu- Gallagher, R.E., Li, Y.-P., Rao, S., Paietta, E., Anderson, J., Etkind,
mor cells, flow cytometry for tumor cell surface antigens, and real- P., Bennett, J.M., Tallman, M.S., and Wiernik, P.H. (1995). Character-
time RT-PCR for PML-RAR and NE expression in tumor cells was ization of acute promyelocytic leukemia cases with PML-RARa
performed as previously described (Westervelt et al., 2003). break/fusion sites in PML exon 6: identification of a subgroup with
decreased in vitro responsiveness to all-trans retinoic acid. Blood
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